Novoheart, AstraZeneca collaborate on human-specific model of HFpEF
The new in-vitro HFpEF model is developed based on Novoheart’s 3-D human ventricular cardiac organoid chamber (hvCOC) technology
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Nov 19
The new in-vitro HFpEF model is developed based on Novoheart’s 3-D human ventricular cardiac organoid chamber (hvCOC) technology
26 Nov 19
Risdiplam is an orally administered liquid, designed to increase and sustain SMN protein levels both in the central…
22 Nov 19
IN.PACT AV DCB enables the drug to penetrate deep into the vessel wall to prevent the restenosis and…
22 Nov 19
bNAbs are the antibodies capable of recognising and blocking the entry of different strains of HIV into healthy…
The party's manifesto says every penny spent on privatisation and outsourcing to healthcare companies is a penny less…
21 Nov 19
GIVLAARI is an RNAi therapeutic designed to target aminolevulinic acid synthase 1 (ALAS1) for the treatment of adults…
20 Nov 19
Daratumumab is a biologic intended to target CD38, a surface protein that is highly expressed across multiple myeloma…
19 Nov 19
The regulator has approved the biosimilar based on the review of a comprehensive data package, demonstrating biosimilarity of…
18 Nov 19
Repatha reduces the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease
18 Nov 19
The study has reached the primary endpoint and has shown consistent safety results of the individual medicines with…